Spots Global Cancer Trial Database for FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer

Official Title: A Phase 2 Study of Single Agent Depsipeptide (FK228) in Gastric and Esophageal Cancers

Study ID: NCT00098527

Conditions

Adenocarcinoma of the Esophagus

Adenocarcinoma of the Stomach

Recurrent Esophageal Cancer

Recurrent Gastric Cancer

Interventions

romidepsin

laboratory biomarker analysis

Study Description

Brief Summary: This phase II trial is studying how well FR901228 works in treating patients with refractory stomach cancer or gastroesophageal junction. Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. FR901228 may also stop the growth of tumor cells by blocking some of the enzymes needed for their growth.

Detailed Description: PRIMARY OBJECTIVES: I. Determine the radiographic response rate (complete response and partial response) in patients with refractory adenocarcinoma of the stomach or gastroesophageal junction treated with FR901228 (depsipeptide). SECONDARY OBJECTIVES: I. Determine the median time to progression and progression-free survival of patients treated with this drug. II. Determine the grade 3 and 4 toxic effects of this drug in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 13-20 patients will be accrued for this study within 6.5-10 months.